Fujirebio Diagnostics Recalls Lumipulse G Beta-Amyloid 1-42-N Plasma Calibrators Due to Inaccurate Test Results
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Fujirebio Diagnostics, Inc. is recalling 128 units of Alzheimer's diagnostic calibrators that may provide falsely elevated positive or indeterminate results.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on February 18, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Devices) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Fujirebio Diagnostics, Inc. has initiated a voluntary Class II recall of its Lumipulse G β-Amyloid 1-42-N Plasma Calibrators. The recall was prompted by the discovery that customers may experience inaccurate test results. Specifically, the product may produce a higher frequency of classifications in the indeterminate and positive zones, or show low specificity compared to FDA-cleared CSF ratio/PET imaging. This is due to falsely elevated positive or indeterminate ratio results.
Which Products Are Affected
The recall affects 128 units distributed nationwide across Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland, Massachusetts, Minnesota, New Jersey, Pennsylvania, Texas, and Washington.
- Product Name: Lumipulse G β-Amyloid 1-42-N Plasma Calibrators
- Model/Catalog Number: 235454
- UDI-DI: 04987270235454
- Lot Numbers: D8C6022U, D8C6044U
- Components: Liquid (Frozen), 1 x 1.5 mL (4 Concentrations: CAL 1, CAL 2, CAL 3, CAL 4)
What You Should Do
Fujirebio Diagnostics, Inc. notified affected customers via letter on December 11, 2025. Facilities and laboratories using these calibrators should immediately check their inventory for the specified lot numbers (D8C6022U and D8C6044U). If these lots are found, users should follow the instructions provided in the firm's notification letter regarding the handling of the affected product. For further inquiries, the recalling firm is located at 201 Great Valley Pkwy, Malvern, PA 19355-1308.
Why This Matters
Inaccurate results from these calibrators can lead to the incorrect classification of a patient as having amyloid pathology associated with Alzheimer’s disease. This may result in a false positive diagnosis or lead to patients undergoing additional, unnecessary clinical testing due to indeterminate results.
Source
This information is based on official recall data provided by the FDA under recall number Z-1306-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.
What is this FDA recall about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more FDA Recalls updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category